IDH1 and central nervous system cancer: In the fifth edition of the “Classification of Central Nervous System Tumors,” IDHm-GBM has been redefined as “IDH-mutant astrocytoma, CNS WHO grade 4,” and GBM diagnosis is only applicable to IDHwt tumors, further establishing the central role of the IDH status in prognosis assessment.9